Younger Chicks Showed Greater THC Cooling and Slower Tolerance in an Age Comparison

A 1973 chicken study found stronger THC-related cooling and slower tolerance development in younger animals. The result is an age-dependent observation in an avian model, not a quantitative prediction for human children or adolescents.

Age was the experimental comparison

Chicks of different ages received THC while researchers measured body temperature and adaptation to repeated exposure. Neonatal animals showed greater hypothermic effects than older animals. Baseline developmental differences can shape a drug response, so results from one age should not automatically represent another.

Tolerance timing also depended on exposure history

Tolerance developed more slowly in younger chicks, but prior administration of a high dose accelerated its development in neonates. Age and prior dose therefore both mattered. The experiment does not establish that a larger pretreatment dose is beneficial or safe.

One endpoint does not represent general neurodevelopment

Body temperature is a physiological response influenced by species and maturation. The abstract does not report human cognition, development, substance use or clinical outcomes. Nor does slower temperature tolerance prove slower adaptation in every organ or behavior.

The study's useful lesson is to retain age and exposure history when comparing tolerance experiments. It cannot establish a human dose conversion, safe threshold or adolescent-risk magnitude. Its species and thermal endpoint sharply limit broader interpretation.

Related: interpreting cannabis tolerance claims.

Research cited

Abel EL; McMillan DE; Harris LS. Tolerance to the hypothermic effects of 9-tetrahydrocannabinol as a function of age in the chicken. British journal of pharmacology (1973). doi:10.1111/j.1476-5381.1973.tb08176.x. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Psychiatric CBD Review’s Recommendation Grades Included Both CBD and THC-Containing Nabiximols

A review published in 2020 graded psychiatric evidence from studies of CBD and CBD-containing nabiximols. Its recommendation labels should not be quoted as though every underlying intervention was purified CBD or every study was randomized. The included designs ranged widely The review identified 23 relevant studies spanning case reports, case…

Spread the love

Read Article: A Psychiatric CBD Review’s Recommendation Grades Included Both CBD and THC-Containing Nabiximols

CBD Eye Research: Molecular Targets and Clinical Ocular Treatment Are Different Evidence Levels

A 2021 ocular CBD review brought together in-vitro and in-vivo research, proposed molecular targets and possible therapeutic applications. This evidence maps a development pathway; it does not establish that CBD products are effective eye treatments. The experimental system belongs in the conclusion A cellular result can identify a target or…

Spread the love

Read Article: CBD Eye Research: Molecular Targets and Clinical Ocular Treatment Are Different Evidence Levels

CBD Addiction Research Measures Reinforcement, Motivation and Withdrawal as Different Outcomes

A 2021 review evaluated CBD research on reinforcing, motivational and withdrawal-related drug effects. These outcomes can inform substance-use-disorder research, but an improvement in one cannot establish successful treatment across all of them. The source combined preclinical and clinical reports The review covered alcohol, opioids, cannabinoids, nicotine and psychostimulants. An animal…

Spread the love

Read Article: CBD Addiction Research Measures Reinforcement, Motivation and Withdrawal as Different Outcomes

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us